| Primary |
| Iron Deficiency Anaemia |
32.0% |
| Drug Use For Unknown Indication |
23.9% |
| Anaemia |
15.1% |
| Iron Deficiency |
8.6% |
| Blood Pressure |
3.0% |
| Hypertension |
2.4% |
| Pain |
1.9% |
| Renal Failure Chronic |
1.6% |
| Supplementation Therapy |
1.6% |
| Premedication |
1.3% |
| Thrombosis Prophylaxis |
1.3% |
| Crohn's Disease |
1.1% |
| Gastric Disorder |
1.1% |
| Erysipelas |
0.8% |
| Iron Deficiency Anemia |
0.8% |
| Malabsorption |
0.8% |
| Prophylaxis |
0.8% |
| Renal Disorder |
0.8% |
| Anemia |
0.5% |
| Anxiety |
0.5% |
|
| Vomiting |
28.2% |
| Urticaria |
10.0% |
| Syncope |
7.1% |
| Dyspnoea |
4.7% |
| Nausea |
4.7% |
| Paraesthesia |
4.7% |
| Oedema Peripheral |
4.1% |
| Urinary Incontinence |
4.1% |
| Swollen Tongue |
3.5% |
| Faecal Incontinence |
2.9% |
| Pruritus |
2.9% |
| Rash |
2.9% |
| Throat Tightness |
2.9% |
| Unresponsive To Stimuli |
2.9% |
| Death |
2.4% |
| Hypotension |
2.4% |
| Loss Of Consciousness |
2.4% |
| Oxygen Saturation Decreased |
2.4% |
| Tachycardia |
2.4% |
| Wrong Technique In Drug Usage Process |
2.4% |
|
| Secondary |
| Drug Use For Unknown Indication |
26.8% |
| Iron Deficiency Anaemia |
17.8% |
| Premedication |
10.3% |
| Blood Pressure |
5.6% |
| Supplementation Therapy |
4.7% |
| Antidepressant Therapy |
3.8% |
| Hypertension |
3.8% |
| Iron Deficiency |
3.8% |
| Pain |
3.8% |
| Anaemia |
2.8% |
| Foetal Exposure During Pregnancy |
2.8% |
| Malabsorption |
2.3% |
| Gastrooesophageal Reflux Disease |
1.9% |
| Prophylaxis |
1.9% |
| Thrombosis Prophylaxis |
1.9% |
| Depression |
1.4% |
| Product Used For Unknown Indication |
1.4% |
| Renal Failure Chronic |
1.4% |
| Anxiety |
0.9% |
| Back Pain |
0.9% |
|
| Vomiting |
22.4% |
| Weight Decreased |
16.3% |
| Faecal Incontinence |
8.2% |
| Urinary Incontinence |
8.2% |
| Oxygen Saturation Decreased |
6.1% |
| Stomatitis |
6.1% |
| Blood Urea Increased |
4.1% |
| Pruritus |
4.1% |
| Cardiac Failure Congestive |
2.0% |
| Cyanosis |
2.0% |
| Death |
2.0% |
| Dizziness |
2.0% |
| Dyspnoea |
2.0% |
| Extravasation |
2.0% |
| Hypotonia |
2.0% |
| Joint Swelling |
2.0% |
| Klebsiella Bacteraemia |
2.0% |
| Loss Of Consciousness |
2.0% |
| Off Label Use |
2.0% |
| Presyncope |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
59.4% |
| Drug Use For Unknown Indication |
10.4% |
| Nuclear Magnetic Resonance Imaging |
6.6% |
| Hyperparathyroidism Secondary |
4.2% |
| Hypertension |
4.1% |
| Angiogram |
2.7% |
| Anaemia |
2.1% |
| Renal Failure Chronic |
2.0% |
| Pain |
1.5% |
| Iron Deficiency Anaemia |
1.0% |
| Hyperparathyroidism |
1.0% |
| Nausea |
1.0% |
| Nuclear Magnetic Resonance Imaging Brain |
0.6% |
| Pneumonia |
0.6% |
| Renal Failure |
0.6% |
| Hyperphosphataemia |
0.5% |
| Supplementation Therapy |
0.5% |
| Dialysis |
0.5% |
| Computerised Tomogram |
0.4% |
| Diarrhoea |
0.4% |
|
| Drug Ineffective |
11.5% |
| Skin Tightness |
11.0% |
| Therapeutic Response Decreased |
7.0% |
| Death |
6.0% |
| Shunt Occlusion |
6.0% |
| Shunt Thrombosis |
4.5% |
| Syncope |
4.5% |
| Cardiac Arrest |
4.0% |
| Cardiac Failure |
4.0% |
| Nephrogenic Anaemia |
4.0% |
| Pneumonia |
4.0% |
| Renal Failure Acute |
4.0% |
| Subcutaneous Nodule |
4.0% |
| Thrombocytopenia |
4.0% |
| Vertigo |
4.0% |
| Weight Decreased |
4.0% |
| Anaemia |
3.5% |
| General Physical Health Deterioration |
3.5% |
| Hospitalisation |
3.5% |
| Pericardial Effusion |
3.0% |
|
